25 April 2023 | News
More than 3,500 QIAstat-Dx instruments installed worldwide at the end of 2022
Qiagen has announced that its QIAstat-Dx syndromic testing solution is expected to be available soon for use in Japan with a SARS-CoV-2 Respiratory Panel that can detect more than 20 pathogens from a single patient sample.
The availability in Japan is expected in mid-2023 after decisions on reimbursement levels and comes as the next step after the recent granting of IVD approval for the test. The entry into Japan will add to more than 100 countries worldwide – including the United States, as well as countries across Europe and other areas of the world – where QIAstat-Dx solutions and various syndromic tests to diagnose diseases are available.
The system is designed to operate in laboratories and employs cost-efficient, single-use cartridges with all reagents on board and built-in sample processing.
Using multiplex real-time PCR, QIAstat-Dx detects and differentiates between multiple pathogens. QIAstat-Dx is the only syndromic testing system to provide Ct values and easy access to amplification curves. Access to this supplementary data provides additional insight, allowing for better-informed decisions for patients.
With more than 3,500 systems installed worldwide at the end of 2022, QIAstat-Dx is used in hospitals, laboratories and clinics as an easy-to-use solution for reliable diagnosis of various diseases. The first group of panels available are for the detection of respiratory or gastrointestinal pathogens or for distinguishing between meningitis and encephalitis infections.